Also known as:HGH· common shorthandrhGH· scientific shorthand
Growth hormone deficien…
Somatropin (recombinant human growth hormone)
Evidence levelEstablished clinical
Human evidenceSubstantial
Regulatory statusLicensed products exist
What you need to know in 20 seconds
What is it?
191-amino-acid recombinant protein hormone
Research focus
Growth hormone deficiency and other licensed indications
Human evidence
Somatropin has extensive approved replacement evidence in diagnosed growth-hormone deficiency. In healthy older adults, systematic review evidence found modest body-composition changes with increased adverse effects and no basis for a broad anti-ageing claim.
Regulatory status
Multiple licensed somatropin products exist. An unverified product labelled as HGH or somatropin is not automatically an approved or quality-assured medicine.
Main limitations
That GH replacement evidence in deficiency supports routine anti-ageing, bodybuilding or longevity use in healthy adults.
Safety
Known risks include glucose intolerance, edema, intracranial hypertension and other label-specific warnings; misuse poses additional risks.
i
Somatropin has extensive approved replacement evidence in diagnosed growth-hormone deficiency. In healthy older adults, systematic review evidence found modest body-composition changes with increased adverse effects and no basis for a broad anti-ageing claim.
What the evidence actually supports
✓Use this as the benchmark separating licensed replacement from enhancement use.
✓The site should never merge 'GH works in GHD' with 'GH is proven anti-ageing'.
✓Keep licensed GH replacement and healthy-person anti-ageing claims on separate evidence tracks.
What is not established / key limitations
×Does not establish benefit in healthy people seeking anti-ageing or bodybuilding effects.
×Risks include edema, arthralgia, glucose effects and other dose-related adverse effects.
×Adverse events increased, including edema, arthralgia, carpal tunnel syndrome and gynecomastia; glucose-dysregulation signals were noted.
Selected study & evidence records
Recombinant GH replacement in adult growth-hormone deficiency
GH produced small mean reductions in fat mass and increases in lean mass, with no significant body-weight change and limited effects on other outcomes.
Known risks include glucose intolerance, edema, intracranial hypertension and other label-specific warnings; misuse poses additional risks.
Dose-related fluid retention, arthralgia, glucose/metabolic effects and other class risks require clinical monitoring.
Technical details
Mechanism / biologyBinds GH receptor, increasing IGF-1 and affecting growth, metabolism and body composition.
Route / formulation boundaryQuality, sterility, dose accuracy and authenticity of research-market HGH must be independently verified.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusVerified dosing evidence added. UK licensed adult growth-hormone-deficiency dosing example. See dosing_evidence records for route, regimen, population, duration and source.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
